Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Four-item prognostic index predicts survival in adult Burkitt lymphoma

Publish date:: December 16, 2020

Key clinical point: The Burkitt Lymphoma International Prognostic Index may help guide treatment and clinical trials for patients with high-risk disease.

Major finding: The 3-year progression-free survival was 96% and overall survival was 99% in low-risk patients.

Study details: A retrospective data analysis of 570 U.S. and 457 non-U.S. adults with Burkitt lymphoma.

Disclosures: No study funding source was reported. Dr. Olszewski reported research funding from Spectrum Pharmaceuticals, Genentech, TG Therapeutics, and Adaptive Biotechnologies. Dr. Melani reported no relevant conflicts of interest to declare.

Citation:

Olszewski AJ et al. ASH 2020, Abstract 705.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,